

# UCSF

## UC San Francisco Previously Published Works

### Title

MP28-03 PERCEPTIONS OF OLDER MEN USING A MOBILE HEALTH APPLICATION TO MONITOR LOWER URINARY TRACT SYMPTOMS AND TAMSULOSIN ADVERSE EFFECTS: MIXED-METHODS STUDY

### Permalink

<https://escholarship.org/uc/item/4w1866ft>

### Journal

Journal of Urology, 206(Supplement 3)

### ISSN

0021-0005

### Authors

Wang, Elizabeth Y  
Breyer, Benjamin N  
Lee, Austin  
[et al.](#)

### Publication Date

2021-09-01

### DOI

10.1097/ju.0000000000002025.03

### Copyright Information

This work is made available under the terms of a Creative Commons Attribution License, available at <https://creativecommons.org/licenses/by/4.0/>

Peer reviewed



1a. Variability in Benign Prostatic Hyperplasia Medication Pricing Based on Pharmacy Type				
Upper East Side				
	Chain (CP) - Median (IQR)	Independent (IP) - Median (IQR)	Online (OP) - Median (IQR)	ANOVA p-value [a]
<b>PDE5</b>				
Tadalafil (5mg qD)	\$264.59 (261.99, 264.59)	\$62.50 (44.25, 86.24)	\$36.30 (32.70, 54.71)	<0.01
<b>5-ARI</b>				
Finasteride (5mg)	\$87.99 (74.59, 87.99)	\$30 (15.71, 50.88)	\$13.95 (8.25, 21.08)	<0.01
Dutasteride (0.5mg)	\$181.99 (165.99, 181.99)	\$30 (22.50, 59.25)	\$22.05 (15.21, 26.55)	<0.01
<b>Alpha Blocker</b>				
Tamsulosin (0.4mg)	\$88.49 (87.99, 88.49)	\$30 (15, 40)	\$14.88 (7.29, 18.83)	<0.01
Doxazosin (8mg)	\$26.99 (18.99, 26.99)	\$30 (19.48, 51)	\$15.30 (10.35, 20.55)	0.04
Alfuzosin (10mg)	\$42.39 (37.59, 42.39)	\$37 (18.47, 72.50)	\$12.90 (7.65, 24.23)	0.06
Sildenafil (8mg)	\$188.49 (186.99, 188.49)	\$65 (45, 120)	\$32 (29.10, 63)	<0.01
Tadalafil (10mg)	\$21.99 (19.19, 21.99)	\$30 (19.99, 48.06)	\$12.15 (7.20, 19.20)	<0.01
<b>Antispasmodic</b>				
Oxybutynin IR (5 mg TID)	\$45.99 (45.59, 57.59)	\$53.50 (28.75, 94.94)	\$36.15 (23.64, 55.65)	0.14
Oxybutynin ER (5 mg qD)	\$120.99 (98.59, 120.99)	\$50 (32.50, 94)	\$16.50 (14.25, 26.78)	<0.01
Mirabegron (25mg)	\$519.99 (487.99, 519.99)	\$482.50 (446.21, 491.25)	\$441.90 (435.90, 453.60)	<0.01
Tolterodine ER (4mg)	\$219.99 (197.99, 219.99)	\$70 (55, 112.50)	\$62.85 (58.20, 74.48)	<0.01
	CP vs IP p-value [b]	Factor Difference (CP/IP) [c]	IP vs OP p-value [b]	Factor Difference (IP/OP) [c]
<b>PDE5</b>				
Tadalafil (5mg qD)	<0.01	4.23	<0.01	1.72
<b>5-ARI</b>				
Finasteride (5mg)	<0.01	2.93	<0.01	2.15
Dutasteride (0.5mg)	<0.01	6.07	<0.01	1.36
<b>Alpha Blocker</b>				
Tamsulosin (0.4mg)	<0.01	2.95	<0.01	2.02
Doxazosin (8mg)	0.06	0.90	0.01	1.96
Alfuzosin (10mg)	0.73	1.15	<0.01	2.87
Sildenafil (8mg)	<0.01	2.90	<0.01	2.03
Tadalafil (10mg)	<0.01	0.73	0.02	2.47
<b>Antispasmodic</b>				
Oxybutynin IR (5 mg TID)	0.10	0.85	0.11	1.48
Oxybutynin ER (5 mg qD)	0.09	2.42	<0.01	3.03
Mirabegron (25mg)	<0.01	1.08	<0.01	1.09
Tolterodine ER (4mg)	<0.01	3.14	<0.01	1.11
East Harlem				
	Chain (CP) - Median (IQR)	Independent (IP) - Median (IQR)	Online (OP) - Median (IQR)	ANOVA p-value [a]
<b>PDE5</b>				
Tadalafil (5mg qD)	\$264.59 (263.94, 319.99)	\$40 (22, 60)	\$36.30 (32.70, 54.71)	<0.01
<b>5-ARI</b>				
Finasteride (5mg)	\$87.99 (84.64, 99.99)	\$15 (10, 20)	\$13.95 (8.25, 21.08)	<0.01
Dutasteride (0.5mg)	\$177.50 (171.25, 181.99)	\$20 (15, 25)	\$22.05 (15.21, 26.55)	<0.01
<b>Alpha Blocker</b>				
Tamsulosin (0.4mg)	\$88.49 (86.37, 103)	\$15 (10, 20)	\$14.88 (7.29, 18.83)	<0.01
Doxazosin (8mg)	\$26.99 (24.99, 47)	\$20 (14.50, 30)	\$15.30 (10.35, 20.55)	0.02
Alfuzosin (10mg)	\$42.39 (41.19, 110)	\$20 (15, 25)	\$12.90 (7.65, 24.23)	<0.01
Sildenafil (8mg)	\$188.49 (188.12, 230)	\$36 (25.50, 45)	\$32 (29.10, 63)	<0.01
Tadalafil (10mg)	\$21.99 (21.29, 46)	\$20 (15, 25)	\$12.15 (7.20, 19.20)	0.02
<b>Antispasmodic</b>				
Oxybutynin IR (5 mg TID)	\$51.59 (45.59, 72)	\$30 (25, 40)	\$36.15 (23.64, 55.65)	0.01
Oxybutynin ER (5 mg qD)	\$115.50 (107.15, 120.99)	\$25 (20, 30)	\$16.50 (14.25, 26.78)	<0.01
Mirabegron (25mg)	\$519.99 (511.99, 535)	\$422.50 (400, 450)	\$441.90 (435.90, 453.60)	<0.01
Tolterodine ER (4mg)	\$219.99 (214.49, 247)	\$45 (37.50, 90)	\$62.85 (58.20, 74.48)	<0.01
	CP vs IP p-value [b]	Factor Difference (CP/IP) [c]	IP vs OP p-value [b]	Factor Difference (IP/OP) [c]
<b>PDE5</b>				
Tadalafil (5mg qD)	<0.01	6.61	<0.01	1.10
<b>5-ARI</b>				
Finasteride (5mg)	<0.01	5.87	<0.01	1.08
Dutasteride (0.5mg)	<0.01	8.87	<0.01	0.91
<b>Alpha Blocker</b>				
Tamsulosin (0.4mg)	<0.01	5.90	<0.01	1.01
Doxazosin (8mg)	0.02	1.35	0.02	1.31
Alfuzosin (10mg)	<0.01	2.12	0.01	1.55
Sildenafil (8mg)	<0.01	5.24	<0.01	1.13
Tadalafil (10mg)	0.03	1.10	0.04	1.65
<b>Antispasmodic</b>				
Oxybutynin IR (5 mg TID)	<0.01	1.72	0.24	0.83
Oxybutynin ER (5 mg qD)	<0.01	4.62	<0.01	1.52
Mirabegron (25mg)	<0.01	1.23	<0.01	0.96
Tolterodine ER (4mg)	<0.01	4.89	<0.01	0.72

Source of Funding: None

### MP28-03 PERCEPTIONS OF OLDER MEN USING A MOBILE HEALTH APPLICATION TO MONITOR LOWER URINARY TRACT SYMPTOMS AND TAMSULOSIN ADVERSE EFFECTS: MIXED-METHODS STUDY

Elizabeth Y. Wang\*, New York, NY; Benjamin N. Breyer, Austin Lee, Natalie Rios, Akinyemi Oni-Orisan, Michael A. Steinman, Ida Sim, Stacey A. Kenfield, Scott R. Bauer, San Francisco, CA

WITHDRAWN

### MP28-04 THE 10-ITEM LURN SYMPTOM INDEX DETECTS ADDITIONAL SYMPTOMS AND SHOWS CONVERGENT VALIDITY WITH THE AUA-SI IN MEN WITH BENIGN PROSTATIC HYPERPLASIA

Clark Judge\*, Tanya Kristof, Chicago, IL; Richard Fantus, Brian Helfand, Evanston, IL; Abigail Smith, Ann Arbor, MI; James Griffith, Chicago, IL; Alexander Glaser, Evanston, IL

**INTRODUCTION AND OBJECTIVE:** The Lower Urinary Tract Dysfunction Research Network (LURN) developed a 10-item symptom index (LURN SI-10) designed for practical clinical use in both men and women for the assessment of lower urinary tract symptoms (LUTS). In this study, we compare the LURN SI-10 with the widely used American Urological Association Symptom Index (AUA-SI) in men with benign prostatic hyperplasia (BPH)/LUTS to assess validity and determine how frequently the LURN SI-10 identifies symptoms missed by the AUA-SI.

**METHODS:** LURN SI-10 and AUA-SI questionnaires were prospectively administered to men presenting with BPH/LUTS. Post void dribbling (PVD), bladder pain/discomfort, and urgency urinary incontinence (UUI) were considered present if the patient indicated occurrence of about half the time or more. Responses were tabulated and Pearson correlations between LURN SI-10 and AUA-SI scores were assessed.

**RESULTS:** The LURN SI-10 and AUA-SI correlate strongly in men with BPH/LUTS (r=0.81; Figure). The bother item of the LURN-10 also correlates strongly with the quality of life (QoL) section of the AUA-SI (r=0.73). The LURN SI-10 identified PVD in 29% (26/91) of patients, bladder pain/discomfort in 13% (12/91) of patients, and UUI in 16% (15/91) of patients.